HUA TEC INTERNATIONAL CO., LTD.
Update：2026/11/10
Industries
Main Industry
Health Care
Main Product/Service
The "AI Semiconductor Liquid Tumor Imaging Detection System (Nano CAST)" integrates semiconductor manufacturing processes, AI image analysis, optical systems, molecular pathology, and precision machinery technology, representing a next-generation cancer cell detection device.
The content above was translated by Ai
Founded Year
2023
Unified Business No.
54999923
Status
Active
Number of Employees
0
Total capital
10,000,000 (NT$)
Location of Company
Taiwan
, Miaoli County
Overseas Development
France
Company names, registration status, legal representatives, founding years, paid-in capital, registered addresses, and other details are sourced from business registration records maintained by Taiwan’s Administration of Commerce, Ministry of Economic Affairs. Exit status includes Emerging Stock Board listings, M&A, and IPOs. Information on overseas expansion is self-reported by startups.
Note 1: FINDIT compiles company information from public and other sources for reference and does not serve as a point of contact for the companies listed.
Note 2: Some company profiles and product/service descriptions are translated using AI and provided for reference only. In case of discrepancies or ambiguity, the original text prevails.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
HUA TEC INTERNATIONAL's latest product, Nano CAST™, is a next-generation cancer detection platform that combines semiconductor-based biochips with AI-driven automation. Using only 16 milliliters of blood, the system efficiently isolates circulating tumor cells (CTCs) with over 90 percent capture rate and sensitivity.
The fully automated workflow—covering cell capture, staining, and image recognition—delivers high-precision results within hours, significantly reducing manual labor. The platform supports earlier-stage diagnosis and more accurate precision medicine, offering strong potential for clinical adoption.
The fully automated workflow—covering cell capture, staining, and image recognition—delivers high-precision results within hours, significantly reducing manual labor. The platform supports earlier-stage diagnosis and more accurate precision medicine, offering strong potential for clinical adoption.
The content above was translated by Ai
